Niki BioSolutions Announces New York State Approval for Its APOE Genotyping Test Using Dried Blood Spots, Plasma, and Urine

What happened

Niki BioSolutions said its subsidiary DiamiR received New York State CLEP approval on October 23, 2026, adding dried blood spots, plasma, and urine to the approved specimens for its APOE Genotyping test, which identifies genetic variants linked to Alzheimer's risk.

Confirmed

Global impact / market context

More specimen types may let DiamiR collect samples with less invasive methods, which means simpler collection could support wider test use and more revenue. The approval also meets New York's strict standards for laboratory-developed tests, which may help the company sell into that state.

Analyst inference

The company is clinical-stage, so investors weigh progress in test approvals against the costs of running a laboratory and getting paid for tests. A New York approval shows regulatory execution, but it does not by itself confirm sales, insurance coverage, or demand from doctors.

Analyst inference

What to watch

1. The approval is limited to specimen types for the APOE Genotyping test already approved in August 2025; it does not cover new diseases or new test products. Confirmed
2. Watch whether DiamiR reports test volume or revenue tied to these new specimen types, since adoption by doctors and insurers would show the approval is commercially useful. Analyst inference
3. Watch spending on laboratory operations and test validation, because higher costs could outweigh gains if test orders do not grow after the expanded approval. Analyst inference

Evidence

• globenewswire.com